[ad_1]
The Gamaleya Center in Moscow, developer of the Sputnik V vaccine, announced Wednesday that it is possible to begin mass immunization against the new coronavirus in the coming weeks, after having verified 92% efficacy in clinical trials.
READ ALSO:
The presidents of Russia and Argentina discuss the Sputnik vaccine
The statements came with the voice of Alexánder Gíntsburg, director of the Gamaleya Center, who reported the preliminary results of clinical trials in correspondence with the data already advanced by the Russian Fund for Direct Investments.
An official Gamaleya statement states: “The studies evaluated the vaccine’s effectiveness among more than 16,000 volunteers, 21 days after receiving the first dose of the vaccine or the placebo.”
The Russian SputnikV vaccine is produced in India, Korea and China, but was created by the Gamaleya National Center for Epidemiology and Microbiology of Russia, a prestigious institute created in 1891. There is no reason to doubt its quality and scare people. doing + pic.twitter.com/Pe0FBukzde
– Evelio S. Bello Varela (@bello_evelio)
November 9, 2020
Abunda, in this regard, “20 confirmed cases were included in the statistical analysis, identified in the placebo group and in the vaccinated group, which made it possible to determine that the effectiveness of Sputnik V is 92 percent”.
The statement specifies that “the publication of the interim results of the post-registration clinical trials, which convincingly demonstrate the efficacy of the Sputnik V vaccine, allows mass vaccination of the Russian population against the coronavirus in the coming weeks”.
According to both cases, more than 20,000 volunteers have received the first dose of the vaccine to date, while another 16,000 people have been vaccinated with the first and second doses in clinical trials in 29 medical centers in Russia. .
URGENT‼ ️
The Russian Sputnik V vaccine was 92% effective. This is indicated by the first interim analysis of the third phase of the clinical trials. This was confirmed by the Russian Direct Investment Fund. pic.twitter.com/1sSfB6cDmR– Cynthia García (@cyngarciaradio)
November 11, 2020
Likewise, the drug’s developers noted that the trials recorded no “unexpected unwanted reactions” among the research participants.
At the same time, the specialists point out that “some of the vaccinated” experienced some “short-term” reactions, such as “pain at the vaccine administration site” or “flu-like syndrome with increased body temperature, weakness, tiredness, ache. head “.
According to medical authorities, trial participants are continuously monitored during the clinical study, which will continue for six months, after which a final report will be prepared.
In parallel, Russia has begun testing the Sputnik V coronavirus vaccine on volunteers over the age of 60.
As I pointed out in a journalistic interview, in fact, the National State has the possibility of acquiring, between December and January, 25 million Sputnik V vaccines developed by the Gamaleya Institute of Russia.
– Alberto Fernández (@alferdez)
November 3, 2020
The Sputnik V vaccine, which uses dual-vector human adenovirus technology, was registered in Russia on August 11, and with that early registration it was possible to supply people from high-risk groups amid the pandemic, while on August 25 the health authorities have given the green light to carry out the post-registration tests of Sputnik V and move on to phase 3 of the trials, with 40,000 participants.
[ad_2]
Source link
